Related Experiment Video
Updated: Apr 25, 2026
Generation of Human Neurons and Oligodendrocytes from Pluripotent Stem Cells for Modeling Neuron-Oligodendrocyte Interactions
Published on: November 9, 2020
ERK1/2 pathway-mediated differentiation of IGF-1-transfected spinal cord-derived neural stem cells into
Bo Shi1, Jianxun Ding2, Yi Liu1
1Department of Spine Surgery, First Hospital of Jilin University, Changchun, P. R. China.
Abstract:
Spinal cord injury (SCI) is a devastating event that causes substantial morbidity and mortality, for which no fully restorative treatments are available. Stem cells transplantation offers some promise in the restoration of neurological function but with limitations. Insulin-like growth factor 1 (IGF-1) is a well-appreciated neuroprotective factor that is involved with various aspects of neural cells. Herein, the IGF-1 gene was introduced into spinal cord-derived neural stem cells (NSCs) and expressed steadily. The IGF-1-transfected NSCs exhibited higher viability and were promoted to differentiate into oligodendrocytes. Moreover, the most possible underlying mechanism, through which IGF-1 exerted its neuroprotective effects, was investigated. The result revealed that the differentiation was mediated by the IGF-1 activated extracellular signal-regulated kinases 1 and 2 (ERK1/2) and its downstream pathway. These findings provide the evidence for revealing the therapeutic merits of IGF-1-modified NSCs for SCI.
Insights
Gene-modified neural stem cells (NSCs) expressing insulin-like growth factor 1 (IGF-1) show improved viability and differentiation potential for spinal cord injury (SCI) repair.
Area of Science:
- Neuroscience
- Regenerative Medicine
- Cell Biology
Background:
- Spinal cord injury (SCI) leads to significant disability with limited restorative treatments.
- Neural stem cell (NSC) transplantation shows promise but has limitations.
- Insulin-like growth factor 1 (IGF-1) is a known neuroprotective factor.
Purpose of the Study:
- To enhance spinal cord-derived NSCs by introducing the IGF-1 gene.
- To investigate the therapeutic potential of IGF-1-modified NSCs for SCI.
- To elucidate the underlying molecular mechanisms of IGF-1's neuroprotective effects.
Main Methods:
- Genetic modification of spinal cord-derived NSCs to stably express IGF-1.
- Assessment of cell viability and differentiation capacity of IGF-1-transfected NSCs.
- Investigation of the signaling pathways involved, focusing on ERK1/2 activation.
Main Results:
- IGF-1-transfected NSCs demonstrated significantly higher viability.
- IGF-1 expression promoted NSC differentiation into oligodendrocytes.
- The neuroprotective effects were mediated by IGF-1-activated ERK1/2 signaling.
Conclusions:
- IGF-1 modification enhances the therapeutic potential of NSCs for SCI.
- IGF-1-modified NSCs promote oligodendrocyte differentiation via the ERK1/2 pathway.
- These findings support the development of IGF-1-based NSC therapies for SCI.
